GC Biopharma said on the 1st that it received approval from the Ministery of Food and Drug Safety for a label change to Ferramiflu Premix Injection, the IV bag formulation of the type A and B flu treatment Ferramiflu. The company plans to supply the product to medical institutions starting this month ahead of the full-blown flu season.
Ferramiflu Premix Injection is an injectable flu treatment that, for the first time in Korea, uses peramivir, a neuraminidase inhibitor approved by the U.S. Food and Drug Administration (FDA), as the active ingredient.
The new product was developed as an RTU (Ready-to-Use) IV bag formulation that can be administered immediately without a separate dilution step. It reduces preparation time for medical staff and minimizes potential errors during administration, improving patient safety.
Ferramiflu sees strong demand every flu season. Unlike existing flu treatments that require swallowing tablets or using inhalers, it can be administered as a single dose, a strength recognized in clinical settings.
It is particularly used as a helpful treatment option for children and older adults who have difficulty swallowing medicine, as well as for severe patients who need rapid symptom relief. It is also cited for quickly easing fever and for having relatively fewer side effects such as vomiting and nausea that can appear with oral medications.
A company official said, "With this launch, we have completed our peramivir product portfolio by offering both vial and IV bag formulations," and added, "We will continue to reflect the needs of the clinical setting and provide a safer administration environment."